Open access
Open access
Powered by Google Translator Translator

Cardiomyopathies

2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis

24 Jan, 2023 | 14:29h | UTC

2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee – Journal of the American College of Cardiology

Key Points: 2023 ACC Expert Consensus on Cardiac Amyloidosis – American College of Cardiology

News Release: ACC Expert Consensus Decision Pathway Focuses on Diagnosis and Management of Cardiac Amyloidosis – American College of Cardiology

 

Commentary on Twitter

 


The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies

9 Jan, 2023 | 14:10h | UTC

The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies – European Heart Journal

 

Commentary on Twitter

 


Cohort Study | Prognostic prediction of genotype vs. phenotype in genetic cardiomyopathies.

23 Nov, 2022 | 13:57h | UTC

Prognostic Prediction of Genotype vs Phenotype in Genetic Cardiomyopathies – Journal of the American College of Cardiology

 

Commentary on Twitter

 

Under a Creative Commons license

 


Review | Differing strategies for sudden death prevention in hypertrophic cardiomyopathy.

4 Nov, 2022 | 13:28h | UTC

Differing strategies for sudden death prevention in hypertrophic cardiomyopathy – Heart

 


Consensus Paper | Diagnosis and management of syncope in hypertrophic cardiomyopathy.

31 Oct, 2022 | 13:49h | UTC

Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management – International Journal of Cardiology

 


Cohort Study | Highly malignant disease in childhood-onset arrhythmogenic right ventricular cardiomyopathy.

24 Oct, 2022 | 14:08h | UTC

Highly malignant disease in childhood-onset arrhythmogenic right ventricular cardiomyopathy – European Heart Journal

Editorial: Arrhythmogenic cardiomyopathies in children: seek and you shall find – European Heart Journal

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by-nc/4.0/ License

 


Review | Restrictive cardiomyopathy: definition and diagnosis.

24 Oct, 2022 | 13:58h | UTC

Restrictive cardiomyopathy: definition and diagnosis – European Heart Journal

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by-nc/4.0/ License

 


Review | Cardiac care of children with Duchenne muscular dystrophy (DMD) and females carrying DMD-gene variations.

20 Oct, 2022 | 12:21h | UTC

Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations – openheart

 


Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children and younger adults in the US.

13 Oct, 2022 | 13:51h | UTC

Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States – Annals of Internal Medicine

News Release: Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children, younger adults in the US – American College of Physicians

 

Commentary on Twitter (thread – click for more)

 

Commentary on Twitter

 


Guideline | Evaluation and management of myocarditis.

12 Oct, 2022 | 13:56h | UTC

Brazilian Society of Cardiology Guideline on Myocarditis – 2022 – Arquivos Brasileiros de Cardiologia

 


Cohort Study | Cardiovascular MRI phenotypes and long-term outcomes in patients with suspected cardiac sarcoidosis.

30 Sep, 2022 | 12:39h | UTC

Cardiovascular Magnetic Resonance Imaging Phenotypes and Long-term Outcomes in Patients With Suspected Cardiac Sarcoidosis – JAMA Cardiology (link to abstract – $ for full-text)

Commentary: Cardiovascular magnetic resonance imaging phenotype with pathology-frequent late gadolinium enhancement associated with high-risk of ventricular arrhythmic and heart failure events – Physician’s Weekly

 

Commentary on Twitter

 


Clinical risk score to predict pathogenic genotypes in patients with dilated cardiomyopathy.

26 Sep, 2022 | 11:57h | UTC

Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy – Journal of the American College of Cardiology

Editorial: Genetic Testing for Dilated Cardiomyopathy: Old School Is New School – Journal of the American College of Cardiology

News Release: Scientists develop a tool to determine if dilated cardiomyopathy has a genetic origin  – Centro Nacional de Investigaciones Cardiovasculares Carlos III

 

Commentary on Twitter

 


Retrospective Cohort Study | Natural history of MYH7-related dilated cardiomyopathy.

14 Sep, 2022 | 13:06h | UTC

Natural History of MYH7-related Dilated Cardiomyopathy – Journal of the American College of Cardiology

 


20-year follow-up of a RCT trial | Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy.

26 Jul, 2022 | 13:33h | UTC

Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial – European Heart Journal

Commentary: Immunosuppression may benefit long term in virus-negative inflammatory cardiomyopathy – Healio (free registration required)

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by/4.0/ license

 


RCT | Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.

13 Jul, 2022 | 11:52h | UTC

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy – Journal of the American College of Cardiology

Related: #ACC22 [Not published yet] – RCT: Mavacamten reduces the need for surgical intervention in patients with obstructive hypertrophic cardiomyopathy.

 


RCT | First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation.

11 Jul, 2022 | 12:21h | UTC

First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial – Circulation

 

Commentary on Twitter

 


Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy.

8 Jul, 2022 | 11:53h | UTC

Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia – Clinical Cardiology

Related:

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis – European Heart Journal

Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis – 2021 – Arquivos Brasileiros de Cardiologia

AHA Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases – European Heart Journal

Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association – Circulation

Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis – Canadian Journal of Cardiology

AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management – JACC: CardioOncology

Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis – Circulation: Heart Failure

 


Case Series | Myocardial injury in patients with acute and subacute Chagas Disease in the Brazilian Amazon using cardiovascular magnetic resonance.

5 Jul, 2022 | 11:47h | UTC

Myocardial Injury in Patients With Acute and Subacute Chagas Disease in the Brazilian Amazon Using Cardiovascular Magnetic Resonance – Journal of the American Heart Association


Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator.

5 Jul, 2022 | 11:29h | UTC

Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator – European Heart Journal

Related Study: Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator – European Heart Journal

Editorial: Arrhythmogenic right ventricular cardiomyopathy: the never-ending quest for a risk calculator


Cohort Study | Novel risk prediction model to determine adverse heart failure outcomes in arrhythmogenic right ventricular cardiomyopathy.

4 Jul, 2022 | 11:53h | UTC

Novel Risk Prediction Model to Determine Adverse Heart Failure Outcomes in Arrhythmogenic Right Ventricular Cardiomyopathy – Journal of the American Heart Association

Editorial: Predicting Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy


Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside.

29 Jun, 2022 | 11:01h | UTC

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside – Drugs

 


Brief Review | Never above suspicion: getting to the bottom of cardiac sarcoidosis diagnosis and treatment.

29 Jun, 2022 | 10:50h | UTC

Never Above Suspicion: Getting to the Bottom of Cardiac Sarcoidosis Diagnosis and Treatment – American College of Cardiology

 


Indications and utility of cardiac genetic testing in athletes.

28 Jun, 2022 | 11:03h | UTC

Indications and utility of cardiac genetic testing in athletes – European Journal of Preventive Cardiology

 


Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada.

27 Jun, 2022 | 11:51h | UTC

Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada – JAMA Network Open

Commentary: Young Men’s Myocarditis Risk 5 Times Higher With Moderna vs Pfizer Vax — But Canadian study finds that 8-week interval before second dose attenuates some of the risk – MedPage Today (free registration required)

 


Cohort Study: Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA.

22 Jun, 2022 | 12:07h | UTC

Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases – The Lancet

Commentaries:

COVID-19 mRNA vaccination and myocarditis or pericarditis – The Lancet

Myocarditis and Pericarditis After the COVID-19 mRNA Vaccination – American College of Cardiology

Related:

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents – JAMA Cardiology

Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals – UK Health Security Agency

Myocarditis following a third Pfizer vaccination dose in military recruits in Israel.

Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 


Stay Updated in Your Specialty

No spam, just news.